Notice of Application - 2012
[Federal Register Volume 77, Number 24 (Monday, February 6, 2012)]
[Notices]
[Pages 5847-5848]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-2581]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on November 15, 2011, Sigma
Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick,
Massachusetts 01760-2447, made application by renewal to the Drug
Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the following basic classes of controlled substances:
| Drug |
Schedule |
| Cathinone (1235) |
I |
| Methcathinone (1237) |
I |
| 4-methyl-N-methylcathinone (1248) |
I |
| Aminorex (1585) |
I |
| Alpha-ethyltryptamine (7249) |
I |
| Lysergic acid diethylamide (7315) |
I |
| 3,4-methylenedioxypyrovalerone (7535) |
I |
| 3,4-methylenedioxy-N-methylcathinone (7540) |
I |
| Tetrahydrocannabinols (7370) |
I |
| 4-Bromo-2,5-dimethoxyamphetamine (7391) |
I |
| 4-Bromo-2,5-dimethoxyphenethylamine (7392) |
I |
| 2,5-Dimethoxyamphetamine (7396) |
I |
| 3,4-Methylenedioxyamphetamine (7400) |
I |
| N-Hydroxy-3,4-methylenedioxyamphetamine (7402) |
I |
| 3,4-Methylenedioxy-N-ethylamphetamine (7404) |
I |
| 3,4-Methylenedioxymethamphetamine (MDMA) (7405) |
I |
| Psilocybin (7437) |
I |
| 5-Methoxy-N,N-diisopropyltryptamine (7439) |
I |
| 1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP) (7470) |
I |
| N-Benzylpiperazine (BZP) (7493) |
I |
| Heroin (9200) |
I |
| Normorphine (9313) |
I |
| Amphetamine (1100) |
II |
| Methamphetamine (1105) |
II |
| Nabilone (7379) |
II |
| 1-Phenylcyclohexylamine (7460) |
II |
| Phencyclidine (7471) |
II |
| Cocaine (9041) |
II |
| Codeine (9050) |
II |
| Diprenorphine (9058) |
II |
| Ecgonine (9180) |
II |
| Levomethorphan (9210) |
II |
| Levorphanol (9220) |
II |
| Meperidine (9230) |
II |
| Metazocine (9240) |
II |
| Methadone (9250) |
II |
| Morphine (9300) |
II |
| Thebaine (9333) |
II |
| Levo-alphacetylmethadol (9648) |
II |
| Remifentanil (9739) |
II |
| Sufentanil (9740) |
II |
| Carfentanil (9743) |
II |
| Fentanyl (9801) |
II |
The company plans to manufacture reference standards.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative
[[Page 5848]]
(ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be
filed no later than April 6, 2012.
Dated: January 26, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2012-2581 Filed 2-3-12; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an unofficial version. An official version of this publication may be obtained
directly from the Government Printing Office (GPO). |
